92 related articles for article (PubMed ID: 34537483)
21. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy.
He Y; Lu M; Che J; Chu Q; Zhang P; Chen Y
Front Oncol; 2021; 11():716844. PubMed ID: 34552872
[TBL] [Abstract][Full Text] [Related]
22. Identification of CD8
Li J; Chen H; Bai L; Tang H
BMC Cancer; 2024 Jan; 24(1):53. PubMed ID: 38200408
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma.
Qin R; Jin T; Xu F
Front Immunol; 2023; 14():1326097. PubMed ID: 38187399
[TBL] [Abstract][Full Text] [Related]
24. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.
Peng X; Gong C; Zhang W; Zhou A
Front Oncol; 2022; 12():1091088. PubMed ID: 36727075
[TBL] [Abstract][Full Text] [Related]
25. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.
Liu H; Qin X; Xu Z; Wu M; Lu T; Zhou S; Yao N; Liu S; Shao Y; Han Z
Front Genet; 2022; 13():1000448. PubMed ID: 36160021
[No Abstract] [Full Text] [Related]
26. GLIM-Defined Malnutrition in Patients with Head and Neck Cancer during the Qualification Visit for Home Enteral Nutrition.
Przekop Z; Milewska M; Szostak-Węgierek D; Panczyk M; Sobocki J
Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276861
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
Russo FP; Zanetto A; Pinto E; Battistella S; Penzo B; Burra P; Farinati F
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008926
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis.
Chen S; Yang Y; Wang R; Fang J
Oral Oncol; 2023 Oct; 145():106479. PubMed ID: 37478574
[TBL] [Abstract][Full Text] [Related]
29. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
[TBL] [Abstract][Full Text] [Related]
31. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S
BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
[TBL] [Abstract][Full Text] [Related]
33. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
[TBL] [Abstract][Full Text] [Related]
34. Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma.
Liu T; Li Q; Lin Z; Wang P; Chen Y; Fu Y; Ding Z
Int Immunopharmacol; 2021 Nov; 100():108128. PubMed ID: 34537483
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
